Biocon Biologics Unlocks European Denosumab Biosimilar Market, Concluding Protracted Intellectual Property Discussions with Amgen Inc. for Commercialization.

Biocon Biologics and Amgen Reach Landmark Settlement to Commercialize Denosumab Biosimilars Across Europe

Tuesday's Landmark Settlement Finalizes Biocon Biologics' Path to Commercialize Denosumab Biosimilars in Europe, Ending Previous Market Entry Barriers.

For more news on stock markets visit our website <a href='https://www.stockmarkets.co.in' target='_blank'>www.stockmarkets.co.in</a>